FARESTOS 20 - Pharmacom Labs

Toremifene is a SERM closely related to tamoxifen, aimed at treating metastatic breast cancer in postmenopausal patients. Developed in 1981 and entering the market by 1990, it is often found as toremifene citrate. It binds to estrogen receptors, blocking their activity in breast cells, thus limiting tumor growth. Clinical trials have demonstrated its effectiveness, matching tamoxifen’s results, while offering benefits in lipid regulation, improving heart health. Research continues into its use for other cancers, including ovarian and endometrial, as well as exploring further medical applications.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about FARESTOS 20 by Pharmacom Labs, consult with your doctor or healthcare professional.